Annual Cash & Cash Equivalents
$55.52 M
+$18.88 M+51.55%
31 December 2023
Summary:
Viking Therapeutics annual cash & cash equivalents is currently $55.52 million, with the most recent change of +$18.88 million (+51.55%) on 31 December 2023. During the last 3 years, it has risen by +$26.40 million (+90.67%). VKTX annual cash & cash equivalents is now at all-time high.VKTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$50.35 M
+$6.43 M+14.65%
30 September 2024
Summary:
Viking Therapeutics quarterly cash and cash equivalents is currently $50.35 million, with the most recent change of +$6.43 million (+14.65%) on 30 September 2024. Over the past year, it has increased by +$13.16 million (+35.40%). VKTX quarterly cash and cash equivalents is now -74.26% below its all-time high of $195.58 million, reached on 31 March 2024.VKTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VKTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +51.5% | +35.4% |
| 3 y3 years | +90.7% | +347.0% |
| 5 y5 years | +124.0% | +62.7% |
VKTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +110.5% | -74.3% | +347.0% |
| 5 y | 5 years | at high | +562.7% | -74.3% | +1201.0% |
| alltime | all time | at high | -74.3% | >+9999.0% |
Viking Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $50.35 M(+14.6%) |
| June 2024 | - | $43.91 M(-77.5%) |
| Mar 2024 | - | $195.58 M(+252.3%) |
| Dec 2023 | $55.52 M(+51.6%) | $55.52 M(+49.3%) |
| Sept 2023 | - | $37.19 M(-46.5%) |
| June 2023 | - | $69.52 M(+278.6%) |
| Mar 2023 | - | $18.36 M(-49.9%) |
| Dec 2022 | $36.63 M(+38.9%) | $36.63 M(+24.6%) |
| Sept 2022 | - | $29.41 M(+81.2%) |
| June 2022 | - | $16.23 M(+30.3%) |
| Mar 2022 | - | $12.45 M(-52.8%) |
| Dec 2021 | $26.37 M(-9.4%) | $26.37 M(+134.1%) |
| Sept 2021 | - | $11.26 M(+27.6%) |
| June 2021 | - | $8.83 M(-47.5%) |
| Mar 2021 | - | $16.80 M(-42.3%) |
| Dec 2020 | $29.12 M(+247.6%) | $29.12 M(+652.4%) |
| Sept 2020 | - | $3.87 M(-79.4%) |
| June 2020 | - | $18.79 M(+23.1%) |
| Mar 2020 | - | $15.26 M(+82.2%) |
| Dec 2019 | $8.38 M | $8.38 M(-72.9%) |
| Sept 2019 | - | $30.95 M(+61.9%) |
| June 2019 | - | $19.12 M(+33.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $14.34 M(-42.1%) |
| Dec 2018 | $24.78 M(+175.7%) | $24.78 M(-85.4%) |
| Sept 2018 | - | $169.51 M(+389.8%) |
| June 2018 | - | $34.61 M(-4.8%) |
| Mar 2018 | - | $36.36 M(+304.5%) |
| Dec 2017 | $8.99 M(+192.2%) | $8.99 M(+250.0%) |
| Sept 2017 | - | $2.57 M(-24.3%) |
| June 2017 | - | $3.39 M(-22.1%) |
| Mar 2017 | - | $4.36 M(+41.7%) |
| Dec 2016 | $3.08 M(+300.2%) | $3.08 M(+0.7%) |
| Sept 2016 | - | $3.05 M(-40.8%) |
| June 2016 | - | $5.16 M(+30.3%) |
| Mar 2016 | - | $3.96 M(+415.1%) |
| Dec 2015 | $768.50 K(+1.7%) | $768.50 K(-64.1%) |
| Sept 2015 | - | $2.14 M(-77.5%) |
| June 2015 | - | $9.50 M(+2804.3%) |
| Mar 2015 | - | $327.00 K(-56.7%) |
| Dec 2014 | $755.90 K(+320.9%) | $755.90 K(-15.2%) |
| June 2014 | - | $891.50 K(+1031.3%) |
| Mar 2014 | - | $78.80 K |
| Dec 2013 | $179.60 K(>+9900.0%) | - |
| Dec 2012 | $0.00 | - |
FAQ
- What is Viking Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Viking Therapeutics?
- What is Viking Therapeutics annual cash & cash equivalents year-on-year change?
- What is Viking Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Viking Therapeutics?
- What is Viking Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Viking Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VKTX is $55.52 M
What is the all time high annual cash & cash equivalents for Viking Therapeutics?
Viking Therapeutics all-time high annual cash & cash equivalents is $55.52 M
What is Viking Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VKTX annual cash & cash equivalents has changed by +$18.88 M (+51.55%)
What is Viking Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VKTX is $50.35 M
What is the all time high quarterly cash and cash equivalents for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash and cash equivalents is $195.58 M
What is Viking Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VKTX quarterly cash and cash equivalents has changed by +$13.16 M (+35.40%)